These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22304580)

  • 1. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.
    Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
    Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
    Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
    Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.
    Parmar S; Seeringer A; Denich D; Gärtner F; Pitterle K; Syrovets T; Ohmle B; Stingl JC
    Pharmacogenomics; 2011 Apr; 12(4):503-14. PubMed ID: 21521023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the relationship between human cytidine deaminase gene polymorphisms and Ara-C sensitivity].
    Chen XW; Yue LJ; Li CR; Li CG; Shi HS; Zhang M
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):459-63. PubMed ID: 19035178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.
    Hyo Kim L; Sub Cheong H; Koh Y; Ahn KS; Lee C; Kim HL; Doo Shin H; Yoon SS
    J Hum Genet; 2015 Dec; 60(12):749-54. PubMed ID: 26354033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
    Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
    Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
    Mahlknecht U; Dransfeld CL; Bulut N; Kramer M; Thiede C; Ehninger G; Schaich M
    Leukemia; 2009 Oct; 23(10):1929-32. PubMed ID: 19458626
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines.
    Ge Y; Jensen TL; Stout ML; Flatley RM; Grohar PJ; Ravindranath Y; Matherly LH; Taub JW
    Cancer Res; 2004 Jan; 64(2):728-35. PubMed ID: 14744791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
    Fanciullino R; Farnault L; Donnette M; Imbs DC; Roche C; Venton G; Berda-Haddad Y; Ivanov V; Ciccolini J; Ouafik L; Lacarelle B; Costello R
    Blood Adv; 2018 Mar; 2(5):462-469. PubMed ID: 29490977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
    Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
    J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
    Medina-Sanson A; Ramírez-Pacheco A; Moreno-Guerrero SS; Dorantes-Acosta EM; Sánchez-Preza M; Reyes-López A
    Biomed Res Int; 2015; 2015():309491. PubMed ID: 26090398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
    Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.
    Bhatla D; Gerbing RB; Alonzo TA; Conner H; Ross JA; Meshinchi S; Zhai X; Zamzow T; Mehta PA; Geiger H; Perentesis J; Davies SM
    Br J Haematol; 2009 Feb; 144(3):388-94. PubMed ID: 19036079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
    Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
    J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
    Flasshove M; Strumberg D; Ayscue L; Mitchell BS; Tirier C; Heit W; Seeber S; Schütte J
    Leukemia; 1994 May; 8(5):780-5. PubMed ID: 7514246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.